Xenon Pharmaceuticals paused enrollment in its phase 3 major depressive disorder and bipolar disorder program for azetukalner after neuropsychiatric adverse events emerged in the larger patient population. The company said existing enrollees will continue, while the trial is expected to generate data in early 2027.